Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Prospective, Multicenter, Randomized, Parallel-Arm, Double-Masked, Placebo-Controlled Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery

NCT07832552 is registered in ClinicalTrials.gov with Harrow Inc as lead sponsor.

NCT NCT07832552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07832552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Prospective, Multicenter, Randomized, Parallel-Arm, Double-Masked, Placebo-Controlled Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery
Lead sponsor
Harrow Inc
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
May 25, 2026
Completion date
March 31, 2027
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

postoperative ocular inflammation, postoperative ocular pain